The higher dose of LEVE (200 mg/kg) was found to be more effective in reducing the cognitive defects induced by DOX and the treatment also decreased acetylcholinesterase and the levels of neuroinflammatory mediators such as COX-2, PGE2, NF-κB, and TNF-α in brain homogenate. The gene discussed is ACHE; the disease is Cognitive impairment.